Liquid Biopsy Market Over $0.4 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report the Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User indicates that the global liquid biopsy market will see over $0.4bn in revenue in 2017.

The lead analyst of the report said:

“Liquid Biopsies are one of the most exciting sectors of the diagnostics market over the next decade, as increasing acceptance of liquid biopsy methods, coupled with the increase in patient comfort, using a minimally invasive technique, and the increasing aging population, with its associated increase in cancer rates, will all combine to provide perfect circumstances for growth in the market. Although the market is currently small, there will be much growth over the forecast period, leading to opportunities that can be exploited.”
The 204-page report contains 190 tables, charts and graphs that add visual analysis in order to explain developing trends within the liquid biopsy market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading liquid biopsy submarkets with 4 segmentations of the market, namely the liquid biopsy market by sample type (blood, urine, other), biomarker type (CTC, ctDNA, Exosomes), application (Lung Cancer, Gastrointestinal Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Other cancers) and end user (Hospitals, Academic Institutes, Diagnostic Laboratories, Cancer Research Centres).

The 204-page report offers market forecasts and analysis for 5 leading regional and 19 national markets, as well as the rest of Europe, rest of Latin America, Rest of APAC and Rest of MEA markets. In addition, the report contains a dedicated leading companies’ chapter covering more than 8 companies leading the field in liquid biopsy technology.

The Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User report will be of value to anyone who wants to better understand the liquid biopsy market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the liquid biopsy industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever